Latest Articlesddd
Exelixis (EXEL) provided an update that testified to its solid fundamentals, the growth of its approved …
Celyad (CYAD) announced an exclusive agreement with Horizon Discovery Group plc, for the use of its shRNA …
A number of biotech or biopharmaceutical companies have succeeded in the past couple of years in …
The Week in Review #33 WE CALL IT THE BAD MARKET The Federal Reserve’s raising of …
Although the tests are for the prevention of a life-threatening metabolic disorder, the prenatal animal testing …
Tanezumab, an investigational humanized monoclonal antibody developed by Pfizer (PFE) and Eli Lilly (LLY), met all …
IMMUNOTHERAPY The Checkpoint Inhibitors The most revered news was the discovery of the checkpoint proteins on …
The Week in Review #32 POSITIVE NEWS PROTEOSTASIS THERAPEUTICS Cystic Fibrosis Two days ago, a clinical-stage …
Why Portola’s Stock Decline Everybody interested in Portola (PTLA) knows by now that this firm has managed …
VTV Therapeutics’ (VTVT) stock price added over 48% before trading hours today. The news that some …
In two pivotal Phase 3 placebo-controlled trials Regeneron Pharmaceuticals’ (REGN) and Sanofi’s (SNY) drug, Dupixent® (dupilumab), demonstrated a …
Amgen (AMGN) announced that AmgevitaTM, a biosimilar to adalimumab, will launch in markets across Europe beginning on October 16, …
Prohost Letter #424 Following the Stars Less Science and More Logic We reiterate that while a …
Exelixis (EXEL) announced its initiation of a phase 3 pivotal trial (COSMIC-311) of Cabometyx (cabozantinib) in patients …
On Saturday, October 6, 2018, Spark Therapeutics (ONCE) presented positive data from a preclinical trial with SPK-3006 …
Today, Prohost is highlighting news that could be transformative for a clinical-stage immunotherapy firm. The firm …
PTC Therapeutics’ (PTCT) product Risdiplam demonstrated safety and tolerability at all the doses used in the …
The U.S. Food and Drug Administration (FDA) has approved Paratek Pharmaceuticals’ (PRTK) product Seysara™ (sarecycline) for inflammatory lesions of non-nodular …
The Week in Review #31 IN THE DEPARTED WEEK NOVEL MIGRAINE DRUGS ARE APPROVED ELI LILLY …
Seattle Genetics (SGEN) and Takeda Pharmaceutical Limited (TKPYY) announced results from Phase 3 ECHELON-2 clinical trial evaluating Adcetris …
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. Accept Privacy policy
